IBA Molecular picks up two Mallinckrodt plants in nuclear meds deal

Nuclear medicine specialist IBA Molecular has picked up two manufacturing sites, one in the U.S., in its $690 million deal for Mallinckrodt's nuclear medicines portfolio.

France-based IBA Molecular (IBAM) has picked up two manufacturing sites, including one in the U.S., as part of its $690 million deal to buy the nuclear medicines business of Dublin-based Mallinckrodt.

The deal closed Friday, with IBAM getting a nuclear medicines manufacturing plant in the St. Louis, Missouri, area and a sterile-fill pharmaceutical manufacturing facility in Petten, the Netherlands. IBAM is also taking on the 800 employees, including about 350 in Maryland Heights, Missouri, according to Mallinckrodt.

The deal was broken down into approximately $574 million in cash, the assumption of about $39 million in long-term debt and $77 million of contingent consideration. While the nuclear medicines that IBAM bought are sold worldwide, Mallinckrodt said that about two-thirds of the revenue the business generates is from U.S. sales.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Mallinckrodt CEO Mark Trudeau said in a statement when the deal was first announced that the portfolio has been a strong cash-generating business over time, “but with our strategic priorities focused on enlarging our portfolio in the high-growth specialty pharmaceuticals space, we believe the sale of our nuclear imaging portfolio to IBAM is the best solution for both the business itself and Mallinckrodt."

With the deal, IBAM now has 21 production facilities and more than 1,500 employees, said IBAM CEO Renaud Dehareng. “All of this sets us apart and will allow us to deliver superior, sharply focused service to our customers reliably every day," Dehareng said.

Mallinckrodt retains a large manufacturing site in St. Louis. Last summer it said it would be investing $8 million in its St. Louis manufacturing operations. In 2015, it opened a $12 million expansion of the plant.

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.